Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
Revue D'Epidemiologie Et De Sante Publique|December 6, 2005
[Cancer patient's satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response]A Brédart, V Mignot, A Rousseau, et al.
Patient Education and Counseling|August 4, 2004
Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparisonA Brédart, V Mignot, A Rousseau, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2015
Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitorsJeffrey G Varnes, Stefan Geschwindner, Christopher R Holmquist, et al.
Science (New York, N.Y.)|January 26, 2023
Rapid plant trait evolution can alter coastal wetland resilience to sea level riseM L Vahsen, M J Blum, J P Megonigal, et al.
Bulletin Du Cancer|March 1, 1993
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]T Conroy, J Wils, B Paillot, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2001
Development of an EORTC disease-specific quality of life module for use in patients with gastric cancerC W Vickery, J M Blazeby, T Conroy, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 3, 2007
[Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]L Tournier-Rangeard, D Peiffert, C Lafond, et al.
The Journal of Infusional Chemotherapy|January 1, 1995
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancerM Hebbar, J Bonneterre, C Fournier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancerE J Roelofs, D J Wagener, T Conroy, et al.
American Journal of Clinical Oncology|April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study GroupT Conroy, P Cappelaere, M Fabbro, et al.
Pageof 15